# Clinical Trial Landscape: 03_nsclc_egfr_exon19

*Generated: 2026-01-05 06:55:49*

## Summary

- **Total Trials**: 88
- **Flagged for Review**: 0
- **Search Terms Used**: 10

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 22 | █████ 25.0% |
| Phase 1 | 16 | ███ 18.2% |
| Unknown | 14 | ███ 15.9% |
| Not Applicable | 13 | ██ 14.8% |
| Phase 3 | 10 | ██ 11.4% |
| Phase 1/Phase 2 | 9 | ██ 10.2% |
| Phase 2/Phase 3 | 2 |  2.3% |
| Early Phase 1 | 2 |  2.3% |

## Status Distribution

- **Recruiting**: 85 (96.6%)
- **Not yet recruiting**: 2 (2.3%)
- **Enrolling by invitation**: 1 (1.1%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| M.D. Anderson Cancer Center | 5 |
| National Cancer Institute (NCI) | 4 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Dana-Farber Cancer Institute | 2 |
| SWOG Cancer Research Network | 2 |
| Wake Forest University Health Sciences | 2 |
| AbbVie | 2 |
| AstraZeneca | 2 |
| Janssen Research & Development, LLC | 2 |
| UNC Lineberger Comprehensive Cancer Center | 2 |
| University of Colorado, Denver | 2 |
| Mayo Clinic | 2 |
| Amgen | 2 |
| Merck Sharp & Dohme LLC | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Carboplatin | 10 |
| Pembrolizumab | 8 |
| Pemetrexed | 8 |
| Osimertinib | 6 |
| Nivolumab | 6 |
| Cisplatin | 5 |
| Questionnaire Administration | 4 |
| Biospecimen Collection | 4 |
| Magnetic Resonance Imaging | 4 |
| Paclitaxel | 4 |
| Aerobic Training | 4 |
| Quality-of-Life Assessment | 3 |
| Computed Tomography | 3 |
| JAB-23E73 | 3 |
| Survey Administration | 2 |
| Cyclophosphamide | 2 |
| Bevacizumab | 2 |
| Durvalumab | 2 |
| Gemcitabine | 2 |
| Placebo | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 88 |
| South Korea | 16 |
| Japan | 16 |
| Spain | 13 |
| France | 12 |
| China | 12 |
| Canada | 11 |
| United Kingdom | 11 |
| Taiwan | 11 |
| Australia | 11 |
| Italy | 10 |
| Israel | 9 |
| Brazil | 9 |
| Germany | 9 |
| Turkey (Türkiye) | 9 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| EGFR exon 19 deletion | manual | 1.0 |
| NSCLC | manual | 1.0 |
| EGFR exon 19 deletion NSCLC | manual | 1.0 |
| EGFR exon 19 deletion non-small cell lung cancer | llm | 0.9 |
| EGFR exon 19 deletion metastatic NSCLC | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung cancer | llm | 0.8 |
| EGFR p.L858R | llm | 0.9 |
| EGFRp.L858R | llm | 0.8 |
| EGFR-p.L858R | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07158749](https://clinicaltrials.gov/study/NCT07158749) | Not Applicable | Not yet recruiting | Virginia Polytechnic... | Generalized and Domain-Specific Epi... |
| [NCT07155187](https://clinicaltrials.gov/study/NCT07155187) | Phase 2/Phase 3 | Recruiting | AbbVie | Phase 2/3 Open Label Randomized Stu... |
| [NCT07125183](https://clinicaltrials.gov/study/NCT07125183) | Phase 2 | Recruiting | University of Colora... | A Phase II Study on Efficacy and To... |
| [NCT07231159](https://clinicaltrials.gov/study/NCT07231159) | N/A | Recruiting | AdventHealth | Building on Trust: Navigating Preve... |
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | Not Applicable | Recruiting | VA Office of Researc... | Evaluating the Impact of Intermitte... |
| [NCT07132918](https://clinicaltrials.gov/study/NCT07132918) | Phase 2 | Recruiting | University of Wiscon... | The cARdiac Radiation Therapy Spari... |
| [NCT07192900](https://clinicaltrials.gov/study/NCT07192900) | Phase 1 | Not yet recruiting | David Bartlett, MD | Fast TILs to Treat Metastatic Cance... |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | Early Phase 1 | Recruiting | University of Texas ... | Feasibility Study of Personalized U... |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | Phase 1/Phase 2 | Recruiting | University of Arizon... | RAdiation comBined With BIspecific ... |
| [NCT06494488](https://clinicaltrials.gov/study/NCT06494488) | Early Phase 1 | Recruiting | The Miriam Hospital | Differential Thrombogenesis Effects... |
| [NCT06896162](https://clinicaltrials.gov/study/NCT06896162) | Not Applicable | Recruiting | UNC Lineberger Compr... | PROGRESS: Precision Oncology Using ... |
| [NCT07064395](https://clinicaltrials.gov/study/NCT07064395) | Not Applicable | Recruiting | Henry Ford Health Sy... | Bright Light Therapy to Reduce Slee... |
| [NCT06973564](https://clinicaltrials.gov/study/NCT06973564) | Phase 1/Phase 2 | Recruiting | Jacobio Pharmaceutic... | A Phase 1/2a, Multicenter, Open-lab... |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Phase 3 | Recruiting | Children's Oncology ... | Risk Adapted Treatment of Unilatera... |
| [NCT06716580](https://clinicaltrials.gov/study/NCT06716580) | Not Applicable | Recruiting | Dana-Farber Cancer I... | EQUAL: EGFR ctDNA QUantative Assess... |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Phase 2 | Recruiting | Duke University | Safety, Efficacy, and Tumor Immune ... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT06706076](https://clinicaltrials.gov/study/NCT06706076) | Phase 1/Phase 2 | Recruiting | BlossomHill Therapeu... | A Phase 1/2 Open-Label, Multicenter... |
| [NCT05669846](https://clinicaltrials.gov/study/NCT05669846) | Phase 2 | Recruiting | Diwakar Davar | Phase II Feasibility Study of Healt... |
| [NCT06659458](https://clinicaltrials.gov/study/NCT06659458) | N/A | Recruiting | Our Lady of the Lake... | Utilizing Long-read Sequencing to I... |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Phase 2 | Recruiting | Amgen | A Phase 2 Study Evaluating the Effi... |
| [NCT06566443](https://clinicaltrials.gov/study/NCT06566443) | Phase 1 | Recruiting | The Methodist Hospit... | Phase I Trial Evaluating the Safety... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Phase 3 | Recruiting | Bristol-Myers Squibb | A Phase 3, Randomized, Open-label S... |
| [NCT06545331](https://clinicaltrials.gov/study/NCT06545331) | Phase 1 | Recruiting | Exelixis | A Dose-Escalation and Expansion Stu... |
| [NCT06252129](https://clinicaltrials.gov/study/NCT06252129) | Not Applicable | Recruiting | Brigham and Women's ... | Maximizing Lymph Node Dissection on... |
| [NCT06422143](https://clinicaltrials.gov/study/NCT06422143) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | Phase 3 Study of Pembrolizumab in C... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06124508](https://clinicaltrials.gov/study/NCT06124508) | Not Applicable | Recruiting | University of Miami | GUIAR: PromotinG Lung Cancer screen... |
| [NCT06462365](https://clinicaltrials.gov/study/NCT06462365) | Phase 1 | Recruiting | Tr1X, Inc. | Phase I, First in Human, Open Label... |
| [NCT06124118](https://clinicaltrials.gov/study/NCT06124118) | Phase 1 | Recruiting | University of Utah | A Feasibility Study to Evaluate the... |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3 Randomized Open-Label Stu... |
| [NCT06253871](https://clinicaltrials.gov/study/NCT06253871) | Phase 1 | Recruiting | Iambic Therapeutics,... | A Phase 1/1b Study of IAM1363 in Pa... |
| [NCT06225804](https://clinicaltrials.gov/study/NCT06225804) | Phase 1 | Recruiting | Abbisko Therapeutics... | A Phase 1, Open-Label Study of ABSK... |
| [NCT06117774](https://clinicaltrials.gov/study/NCT06117774) | Phase 3 | Recruiting | Amgen | A Phase 3, Randomized, Double-blind... |
| [NCT05925803](https://clinicaltrials.gov/study/NCT05925803) | Phase 3 | Recruiting | AstraZeneca | A Multicenter, Randomized, Parallel... |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Phase 2 | Recruiting | Hackensack Meridian ... | A Multicenter Phase II Randomized T... |
| [NCT05815173](https://clinicaltrials.gov/study/NCT05815173) | Phase 1 | Recruiting | NYU Langone Health | Phase I/II Study of Ladarixin and S... |
| [NCT05845671](https://clinicaltrials.gov/study/NCT05845671) | Phase 1/Phase 2 | Recruiting | University of Colora... | A Phase 1 / 2, Open Label, Study of... |
| [NCT05876923](https://clinicaltrials.gov/study/NCT05876923) | Not Applicable | Recruiting | Mayo Clinic | The Effects of Acute and Chronic Ex... |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Phase 2 | Recruiting | Memorial Sloan Kette... | Window of Opportunity Analysis of P... |
| [NCT05642572](https://clinicaltrials.gov/study/NCT05642572) | Phase 2 | Recruiting | SWOG Cancer Research... | A Randomized Phase II Study of INC2... |
| [NCT05785741](https://clinicaltrials.gov/study/NCT05785741) | Phase 1/Phase 2 | Recruiting | DualityBio Inc. | A Phase 1/2a, Multicenter, Open-Lab... |
| [NCT05720117](https://clinicaltrials.gov/study/NCT05720117) | Phase 1 | Recruiting | Pyxis Oncology, Inc | A First-in-Human, Open-label, Multi... |
| [NCT05761782](https://clinicaltrials.gov/study/NCT05761782) | N/A | Recruiting | University of Califo... | Engaging Diverse and Underserved Co... |
| [NCT05702034](https://clinicaltrials.gov/study/NCT05702034) | Phase 3 | Recruiting | Janssen Research & D... | A Phase 3, Randomized, Double-Blind... |
| [NCT05500092](https://clinicaltrials.gov/study/NCT05500092) | Phase 2 | Recruiting | Montefiore Medical C... | An Open Label, Randomized Study of ... |
| [NCT05514717](https://clinicaltrials.gov/study/NCT05514717) | Phase 1 | Recruiting | Mersana Therapeutics | A Phase 1, First-in-Human, Dose Esc... |
| [NCT05498428](https://clinicaltrials.gov/study/NCT05498428) | Phase 2 | Recruiting | Janssen Research & D... | A Phase 2, Open-Label, Parallel Coh... |

*... and 38 more trials (see trials.csv for full list)*
